Call Us: +1 (306) 715 9460

CQV Archives | Page 2 of 4 | GxP Cellators Consultants Ltd.

by Vinod
04/05/2025
RABS_02-1280x778.webp
Restricted Access Barrier Systems (RABS)0

Restricted Access Barrier Systems (RABS)

What Are RABS?

Restricted Access Barrier Systems (RABS) are advanced containment systems used in pharmaceutical and biotechnology manufacturing environments. They are designed to provide a physical and aerodynamic barrier between the operator and the critical cleanroom environment, particularly aseptic processing zones. RABS limit contamination risks by reducing direct human intervention and maintaining environmental control.

Why Are RABS Being Used?

Restricted Access Barrier Systems (RABS) are being increasingly implemented in pharmaceutical manufacturing environments due to their ability to bridge the gap between traditional cleanroom operations and complete isolator systems. Key reasons for their adoption include:

  • Enhanced Contamination Control
    RABS provides a robust physical and aerodynamic barrier between operators and critical zones, significantly reducing microbial and particulate contamination risk during aseptic processing.
  • Regulatory Compliance
    RABS help manufacturers meet the stringent requirements of international regulatory bodies such as the FDA and EMA and align with cGMP and EU Annex 1 standards, particularly for sterile product manufacturing.
  • Improved Operator Safety
    By minimizing direct contact with open product zones and hazardous substances, RABS enhance occupational safety, especially when handling potent or toxic compounds.
  • Cost-Effective and Flexible
    Compared to isolators, RABS are generally more cost-effective and less complex to retrofit into existing facilities. They offer flexibility for various production scales and are quicker to implement without major structural modifications.

Advanced Therapy Medicinal Products I ATMPs I

 

Types of RABS

1.     Open RABS (oRABS):

Open Restricted Access Barrier Systems (oRABS) are designed to provide a physical barrier between the operator and the critical aseptic zone while maintaining open airflow with the surrounding cleanroom. Key characteristics include:

  • Shared Air Environment
    The system draws air from the surrounding cleanroom (typically Grade B), which is filtered through terminal HEPA filters within the RABS unit.
  • Non-Sealed Design
    While physical barriers such as rigid panels, glove ports, and doors are in place, the system is not airtight. This allows for easier access but requires strict environmental controls.
  • Environmental Requirement
    Due to the system’s open nature, oRABS must be operated within a Grade B cleanroom to maintain the required aseptic conditions in the critical zone (Grade A under RABS).
  • Operator Interventions
    Designed to limit—rather than eliminate—operator interventions, oRABS rely on stringent aseptic techniques and validated procedures.

2.     Closed RABS (cRABS):

Closed Restricted Access Barrier Systems (cRABS) are fully enclosed systems designed to maximize contamination control and minimize operator exposure to critical environments. These systems are more advanced than open RABS and offer enhanced sterility assurance.

  • Fully Enclosed Configuration
    The cRABS maintains a sealed barrier around the aseptic zone, with all operations conducted through glove ports or automation. This enclosure significantly reduces the risk of contamination from human interaction.
  • Integrated HEPA Filtration
    Air supplied to the internal environment is filtered through high-efficiency particulate air (HEPA) filters. The filtered air is recirculated within the enclosure or exhausted depending on the application.
  • Positive Pressure Maintenance
    The internal chamber operates under positive pressure relative to the surrounding environment to prevent ingress of contaminated air in case of minor leaks.
  • Higher Sterility Assurance Level (SAL)
    Combining physical containment with strict airflow control, cRABS offer a higher product protection level than open systems and are suitable for critical aseptic manufacturing processes.

3.     Hybrid RABS:

Hybrid RABS combine key features of both isolators and traditional RABS, offering enhanced contamination control with greater operational flexibility. These systems are often selected when a higher level of sterility assurance is required but full isolator implementation is not feasible.

  • Integrated Design Approach
    Hybrid RABS incorporate structural and operational elements from isolators (e.g., partial enclosure, limited access) while maintaining the ergonomic and cost advantages of RABS.
  • Decontamination Capability
    Some hybrid RABS are designed to support automated decontamination processes, such as hydrogen peroxide (H₂O₂) vapor bio decontamination, to reduce bioburden before aseptic processing begins.
  • Partial Sealing
    While they offer improved containment over open RABS, hybrid systems are not fully sealed like isolators. Controlled access and validated airflows remain critical.
  • Use Cases
    Ideal for operations requiring improved environmental control over open RABS but without the full infrastructure investment needed for isolators

Biosafety Cabinets

 

Qualification of RABS

Qualification Strategy includes DQ, IQ, OQ, and PQ phases, ensuring that the RABS is designed, installed, and functions as intended.

1.     Design Qualification (DQ)

  • Verifies that the design meets user requirements and regulatory expectations.
  • Design review, risk assessments, and documentation of specifications.

2.     Installation Qualification (IQ)

  • Confirms that the RABS system and components are installed correctly.
  • Checks utility connections, component specs, drawings, software versions, etc.

3.     Operational Qualification (OQ)

  • Verifies that the RABS operates within predetermined parameters.
  • Tests include:
    • HEPA filter integrity testing (e.g., DOP/PAO testing)
    • Airflow visualization (smoke studies)
    • Alarm verification
    • Gasket and door seal integrity
    • Pressure decay tests

4.     Performance Qualification (PQ)

  • Demonstrates that the RABS performs effectively in routine operation.
  • Tests include:
    • Environmental monitoring (viable and non-viable particles)
    • Aseptic process simulation (media fill)
    • Operator interventions testing

Overall Qualification Strategy

PhaseFocusKey Activities
DQDesignReview URS, vendor designs, risk assessment
IQInstallationComponent verification, wiring, software validation
OQFunctionAirflow, filter integrity, smoke study, alarms
PQPerformanceMedia fill, EM, process simulation

All qualification phases must be documented and traceable, complying with GxP and Annex 1 requirements.

Pros and Cons of Using RABS

Pros

  • High sterility assurance level
  • Cost-effective vs isolators
  • Lower human intervention
  • Easily retrofitted in existing cleanrooms
  • Flexible operations

Cons

  • Requires controlled cleanroom environment (Grade B or higher)
  • Human intervention still possible (vs isolators)
  • Glove port risks (integrity, ergonomic strain)
  • More maintenance than isolators (especially for open RABS)

Contacting GxP Cellators Consultants

GxP Cellators is a reputed service provider specializing in GxP-compliant validation, qualification, and consulting. We can assist in:

  • Full RABS qualification (DQ to PQ)
  • Risk assessments
  • URS generation and review
  • Smoke studies and airflow visualization
  • Protocol preparation and execution

You can reach out to us through:

  • Website: www.gxpcellators.com
  • Email:
  • Phone: +1-306-715-9460

Cleanroom Documentation | Cleanroom Documentation Package

CONTINUE READING
by Vinod
27/04/2025
GDP_Trailer-1280x853.webp
Good Distribution Practices (GDP)0

Certification of Trailers and Shipping Vessels for GDP Compliance

What is GDP for pharmaceutical distribution?

Good Distribution Practices (GDP) are international guidelines to ensure that medicines are consistently stored, transported, and handled under suitable conditions to ensure quality, safety, and efficacy.

  • GDP focuses not only on warehouses and wholesalers but also heavily on transportation (trailers, shipping vessels, etc.).
  • Transportation must preserve integrity, prevent contamination, maintain controlled conditions (especially temperature-sensitive products), and protect against theft or counterfeiting.

Good Distribution Practices (GDP) Certification

 

General Requirements for Trailers and Shipping Vessels (GDP-compliant Transport)

To qualify shipping trailers and vessels under GDP:

Temperature Control:

  • Capability to maintain required conditions (e.g., 2–8°C for refrigerated, 15–25°C for room temperature).

Calibration and Qualification:

  • Temperature mapping (thermal qualification).
  • Equipment calibration (temperature sensors, humidity sensors, data loggers).

Monitoring:

  • Real-time temperature monitoring with alarms.
  • GPS tracking often required for security and monitoring.

Cleaning & Maintenance:

  • Documented cleaning procedures to avoid contamination.

Security Measures:

  • Tamper-proof systems, sealed trailers, secure loading/unloading procedures.

Change Management and CAPA:

  • Process for corrective actions and preventive actions if issues are found.

Documentation:

  • Transport records, calibration certificates, deviation records, maintenance logs.

Training:

  • Drivers and operators must be trained in GDP and handling requirements.

How to Qualify Shipping Trailers and Vessels for GDP Compliance

Typical steps for qualification:

  • User Requirement Specification (URS): Define what you need (temperature range, payload, security).
  • Design Qualification (DQ): Document that the design meets requirements.
  • Installation Qualification (IQ): Verify installation — equipment matches specification.
  • Operational Qualification (OQ): Test the operational capabilities (like temperature control).
  • Performance Qualification (PQ): Test the trailer/vessel under simulated real-world conditions.
  • Thermal Mapping:
    • Map temperature distribution during empty and loaded conditions.
  • Calibration:
    • Certify all measurement equipment (sensors, loggers).
  • Validation Report:
    • A final summary stating the trailer/vessel is fit for pharmaceutical distribution.

GMP Auditing Services I GMP Audits I GMP Auditors I

 

Regulatory Requirements & Guidelines

Region/AgencyKey GDP Guidance/Requirement
Health CanadaFollows GUI-0069 – Guidelines for Temperature Control of Drug Products during Storage and Transportation
USFDANo separate GDP guideline. Relies on CGMPs (21 CFR parts 210 and 211), especially storage and distribution sections.
EMA/EU-GMPEU GDP Guidelines (2013/C 343/01), very detailed transport and temperature requirements.
WHOWHO Good Distribution Practices for pharmaceutical products TRS 957, Annex 5
ANVISA (Brazil)RDC No. 430/2020 on Good Distribution Practices
TGA (Australia)TGA follows PIC/S GDP Guide for transport and distribution.
MCC (South Africa)Medicines Control Council GDP guidelines follow WHO model closely.

Certification Bodies for Trailers and Vessels

Here’s the nuance: Regulators (Health Canada, FDA, EMA, etc.) do not directly “certify” trailers or vessels.
Instead:

  • Third-party certification bodies provide GDP certification audits for distribution companies, warehouses, and transport equipment.
  • Certification can cover specific trailers/vessels as part of a distribution network’s compliance.

References and Regulations

Special Notes

  • In Canada, Health Canada inspectors will inspect GDP compliance during licensing inspections (Drug Establishment Licenses).
  • In the US, FDA inspects GDP indirectly via CGMP inspections.
  • In EU, national agencies (like MHRA UK, BfArM Germany) inspect GDP compliance directly during licensing or GxP inspections.

Typical Certifications Achievable

✅ GDP Compliance Certificate (for the transport fleet)
✅ ISO 9001 (Quality Management System) – optional but very helpful
✅ ISO 13485 (for medical devices transport) – optional depending on goods
✅ TAPA Certification (for security in transport)

Need GDP Certification for Your Trailers and Shipping Vessels?

If you are planning to obtain Good Distribution Practices (GDP) certification for your trailers, trucks, or shipping vessels, GxP Cellators Consultants is here to help.

We specialize in:

  • Implementing GDP-compliant quality systems,
  • Performing full qualification of transport assets (trailers, reefers, containers, vessels),
  • Conducting temperature mapping, calibration validation, and
  • Preparing comprehensive documentation to support your licensing applications to regulatory agencies such as Health Canada, USFDA, EMA, TGA, and WHO.
  • Ensure your transport fleet meets regulatory requirements before inspection.
  • Avoid costly delays in your licensing process.
  • Work with experienced GxP compliance experts.

Contact GxP Cellators Consultants at to get your trailers and shipping vessels fully qualified and GDP-ready!

 

CONTINUE READING
by Vinod
25/04/2025
Fill-Finish-1280x853.webp
Media Fill0

Media Fill: A Critical Validation Process in Aseptic Manufacturing

What is Media Fill?

A Media Fill, also known as a Process Simulation, is a critical microbiological validation technique used in aseptic manufacturing. This test replaces the actual pharmaceutical product with a sterile nutrient-rich growth medium (commonly Tryptic Soy Broth) to simulate the entire aseptic production process.

The purpose is to assess whether the manufacturing operations, including equipment, environment, and personnel practices, can consistently prevent microbial contamination. It is a fundamental requirement to ensure the sterility of parenteral drug products and to meet international regulatory standards.

Vaccines | Vaccine Facility Qualifications | Vaccine Cleanrooms

 

Why is Media Fill Required?

Media Fills are essential for:

  • Demonstrating the sterility assurance of aseptic processing
  • Confirming that procedures, personnel, equipment, and environment consistently prevent contamination
  • Meeting global regulatory requirements for sterile pharmaceutical products

Media Fill Process Overview

Using a microbial growth medium, a Media Fill (Process Simulation) replicates your routine aseptic manufacturing operations. Below is a step-by-step outline:

1.     Preparation & Planning

  • Define the scope: product lines, fill volumes, and critical interventions to simulate.
  • Select and qualify a growth medium (e.g., Tryptic Soy Broth) that supports a broad spectrum of microorganisms.
  • Establish pass/fail criteria (typically zero positives per batch).

2.     Environmental & Equipment Setup

  • Ensure all equipment (sterile filling lines, isolators, lyophilizers) is cleaned, sterilized, and qualified.
  • Verify cleanroom classification (Grade A in B background) and complete airborne particle/environmental monitoring.

3.     Operator Gowning & Training

  • Operators do gowning per SOPs for aseptic operations.
  • Each intervention (e.g., needle change, line stop) is pre-planned and rehearsed.

4.     Simulated Aseptic Filling

  • Replace the drug product with sterile medium.
  • Run a full production batch, including all routine and off-normal interventions.
  • Document each step in real time: start/end times, deviations, and operator actions.

5.     Incubation & Inspection

  • Incubate filled units at the specified temperature (e.g., 20–25 °C for 7 days, then 30–35 °C for 7 days).
  • Examine visually for turbidity or pellet formation indicating microbial growth.

6.     Data Analysis & Reporting

  • Record the number of contaminated units.
  • Compare against acceptance criteria (e.g., 0 positives per 100 units).
  • Investigate any failures, perform root-cause analysis, and implement corrective actions.

7.     Requalification & Trending

  • Schedule media fills at least semi-annually or after significant process/facility changes.
  • Trend results over time to demonstrate ongoing process control.

Terminal Sterilization and Aseptic Sterilization

 

Prime Components of Media Fills

Successful execution of a Media Fill depends on integrating critical components that mirror real-world aseptic manufacturing. These include:

  • Trained Aseptic Operators

    Personnel must be fully qualified in aseptic techniques, gowning procedures, and routine/intervention handling within cleanroom environments.

  • Controlled Cleanroom Environment (Grade A/B)

    To ensure contamination control, media fills must be conducted under strict environmental conditions—typically Grade A laminar airflow within a Grade B background.

  • Validated Equipment and Materials

    All production equipment, transfer tools, and single-use systems must be cleaned, sterilized, and validated for aseptic compatibility.

  • Simulated Interventions

    Routine and non-routine activities—such as needle changes, line stoppages, and equipment adjustments—must be incorporated to mimic actual manufacturing conditions.

  • Sterile Media (e.g., Tryptic Soy Broth – TSB)

    To simulate product filling, a broad-spectrum microbial growth medium must be used. The medium must be sterile, clear, and free of growth inhibitors.

  • Incubation and Inspection Protocols

    Filled units are incubated under validated conditions (typically 14 days) and visually inspected for turbidity or microbial growth, indicating a breach in aseptic integrity.

Regulatory Requirements for Media Fills

Media Fill testing (aseptic process simulation) is mandatory for sterile pharmaceutical manufacturing and strictly regulated by global health authorities. These tests are essential to demonstrating the reliability of aseptic operations and maintaining regulatory compliance.

Key Regulatory Guidelines:

Standard Regulatory Expectations:

  • Routine Execution:

    Media Fills must be performed at least twice yearly (semi-annually) for each aseptic process line.

  • Re-Validation Triggers:

    Requalification is required after:

    • Equipment upgrades or replacements
    • Process changes or procedural updates
    • Facility renovations or layout modifications
    • Significant deviations or contamination events

  • Acceptance Criteria:

    Zero contamination is expected in most cases. The number of units filled and accepted depends on batch size and risk-based assessment.

Need Support?

GxP Cellators Consultants offer expert guidance on designing, executing, and interpreting Media Fills in line with global regulatory expectations.

📧 Contact:
Let our team help ensure your aseptic processes meet compliance standards and inspection-readiness.

CONTINUE READING
by Vinod
23/04/2025
ATMP22042025.webp
Advanced Therapy Medicinal Products0

Advanced Therapy Medicinal Products (ATMPs)

Advanced Therapy Medicinal Products (ATMPs) are an emerging class of medicines based on genes, cells, or tissues that offer revolutionary treatment options, especially for diseases that are currently untreatable or poorly managed with conventional pharmaceuticals.

What are ATMPs?

Advanced Therapy Medicinal Products (ATMPs) are innovative biopharmaceuticals that utilize genes, cells, or engineered tissues to treat, prevent, or potentially cure a wide range of serious diseases. These therapies are particularly promising for conditions such as genetic disorders, cancers, autoimmune diseases, and tissue/organ damage, where conventional pharmaceuticals often fall short.

Types of ATMPs:

1.     Gene Therapy Medicinal Products (GTMPs):

  1. Deliver functional genes to replace faulty ones or to provide new functions.
  2. Example: Zolgensma (for spinal muscular atrophy).

Revolution in Cell and Gene Therapy | Cell Therapy | Cleanrooms

2.     Somatic Cell Therapy Medicinal Products (sCTMPs):

  1. Use cells manipulated outside the body and reintroduced to repair or modify tissue function.
  2. Example: Provenge (for prostate cancer).

3.     Tissue-Engineered Products (TEPs):

  1. Use engineered cells or scaffolds to repair, regenerate, or replace damaged tissues.
  2. Example: Holoclar (for corneal repair using limbal stem cells).

4.     Combined ATMPs:

  1. Include one above integrated with a medical device (e.g., scaffolds, matrices).
  2. Example: A tissue-engineered cartilage product with a biodegradable implant.

 

Significance of ATMPs over Traditional Pharmaceuticals

 

FeatureTraditional DrugsATMPs
MechanismChemical or biological activityCell, gene, or tissue-based therapeutic action
TargetOften symptom-basedOften root cause or regenerative
CustomizationStandardized (mass-produced)Often patient-specific (e.g., autologous therapies)
Therapeutic ScopeChronic disease managementCurative potential in many cases
ExamplesStatins, antibiotics, insulinCAR-T cells, CRISPR-based gene editing, stem cell therapies

Challenges with ATMPs and GMP (Good Manufacturing Practice)

Advanced Therapy Medicinal Products (ATMPs) development and production present unique challenges beyond conventional pharmaceutical manufacturing. Due to their biological nature and high degree of customization, maintaining compliance with Good Manufacturing Practice (GMP) standards is significantly more complex.

1.      Product Complexity

  • Biological Instability: ATMPs involve living cells, viral vectors, or inherently fragile genetic constructs and are prone to degradation.
  • Variability: Biological raw materials and processes introduce high variability, making achieving batch-to-batch consistency difficult.

2.     Manufacturing Challenges

  • Personalization: Many ATMPs are autologous, requiring manufacturing steps tailored to each individual patient.
  • Scale and Infrastructure: Production is often small-scale, and requires specialized cleanrooms, closed systems, and aseptic processing to maintain sterility and viability.

3.     Supply Chain Issues

  • Limited Shelf Life: Most ATMPs have short shelf life, sometimes just hours or days, demanding real-time coordination.
  • Cold Chain Logistics: Strict temperature controls are needed throughout the supply chain to preserve product integrity.
  • Just-in-Time Delivery: Manufacturing, testing, and delivery must be highly synchronized with clinical administration windows.

4.     Quality Control (QC)

  • Limited Material for Testing: ATMPs are often produced in small batches with minimal excess material for quality testing.
  • Complex In-Process Testing: Real-time monitoring of biological activity, identity, purity, and potency is essential and technically demanding.

5.     GMP Compliance Challenges

  • Rigid Frameworks vs. Flexible Needs: Traditional GMP standards may not accommodate the dynamic nature of ATMP development, especially for individualized therapies.
  • Hospital-Based Manufacturing: Integrating GMP principles in hospital or academic settings (for autologous or early-phase therapies) poses logistical and regulatory hurdles.
  • Evolving Standards: Regulatory expectations and GMP guidelines for ATMPs still evolve and may vary across regions.

Cell and Gene Therapies I CMC | CMC Safety

 

Regulatory Approach on ATMPs

1.      EMA (European Medicines Agency) – EU

  • Regulation: ATMPs in the European Union are governed by Regulation (EC) No 1394/2007, specifically designed to ensure the safety and efficacy of gene therapy, somatic cell therapy, and tissue-engineered products.
  • Specialized Committee: The Committee for Advanced Therapies (CAT) evaluates the scientific aspects of ATMPs, ensuring they meet stringent standards for approval.
  • Centralized Marketing Authorization: Centralized approval through the EMA is required for marketing ATMPs across all EU member states.
  • Hospital Exemption (Article 3): Allows certain non-routine, personalized treatments (e.g., autologous therapies) to be exempt from centralized approval, provided they are produced and used within a single hospital or medical institution.

2.     FDA (U.S. Food and Drug Administration) – USA

  • Regulation Body: ATMPs in the U.S. fall under the Center for Biologics Evaluation and Research (CBER) at the FDA, which oversees biologics, including gene therapy and cell therapy products.
  • Regulatory Framework:
    • IND (Investigational New Drug): Required for clinical trials involving ATMPs to assess safety and efficacy before approval.
    • BLA (Biologics License Application): Needed for the commercial approval of ATMPs.
    • Expedited Pathways:
      • RMAT (Regenerative Medicine Advanced Therapy): Provides priority review and more flexible clinical trial designs for promising regenerative therapies.
      • Breakthrough Therapy Designation: Expedited development and review processes for therapies addressing serious or life-threatening conditions.

3.     TGA (Therapeutic Goods Administration) – Australia

  • Regulation: In Australia, ATMPs are regulated under the Biologicals Framework which governs gene therapies, cell therapies, and tissue-engineered products.
  • Risk-Based Classification: ATMPs are classified into four risk classes (Class 1 to 4) based on their complexity, patient risk, and potential for harm.
  • Focus on Patient Safety: Emphasis on autologous therapies, ensuring that the safety of personalized treatments (derived from patient’s own cells) is thoroughly assessed.

4.     MSS (Malaysia’s National Pharmaceutical Regulatory Agency) – Malaysia

  • Regulation: ATMPs are regulated by the Cell and Gene Therapy Products (CGTPs) Guidelines issued by the National Pharmaceutical Regulatory Agency (NPRA).
  • Guideline Focus: These guidelines ensure that cells and gene therapies are handled under strict quality control, emphasizing traceability from collection through processing and administration.
  • Compliance with GMP: ATMPs must comply with GMP and additional regulations specific to cell handling, genetic modifications, and patient safety.

5.     WHO (World Health Organization) – Global

  • Technical Guidance: The WHO provides guidance on regulating cell-based therapies and genetic medicines globally, to ensure safe and ethical practices in developing and using ATMPs.
  • Global Harmonization: The WHO fosters international regulatory harmonization, facilitating easier global access to ATMPs while maintaining safety and efficacy standards.
  • Focus on Low-Income Regions: WHO’s efforts also focus on making advanced therapies accessible and affordable in resource-constrained settings, while ensuring that safety and quality are not compromised.

6.     ANVISA (Agência Nacional de Vigilância Sanitária) – Brazil

  • Regulation: In Brazil, ATMPs are categorized as Advanced Cell Therapy Products (ACTPs), subject to regulatory frameworks set by ANVISA, the Brazilian Health Regulatory Agency.
  • Regulatory Pathway: ANVISA has developed a dedicated regulatory pathway for expedited review, ensuring that promising treatments can be brought to market more quickly in Brazil.
  • Clinical Trial and Approval Process: The approval process includes assessing clinical trial data, safety profiles, and post-market surveillance to ensure the ongoing safety of ATMPs in the population.

Contact Us

For technical, scientific, and GMP consulting services related to your ATMP (Advanced Therapy Medicinal Products) products, please get in touch with GxP Cellators Consultants at .

CONTINUE READING
by Vinod
18/04/2025
GCP_QMS-1280x853.webp
GCP QMS0

GCP QMS: Quality Management System for Sponsor Companies

A Good Clinical Practice Quality Management System (GCP QMS) is a structured framework that ensures sponsor companies maintain compliance with global regulatory standards throughout a clinical trial’s lifecycle. Regulatory bodies such as the FDA (U.S. Food and Drug Administration), ICH (International Council for Harmonisation), and EMA (European Medicines Agency) emphasize the critical role of a robust QMS in safeguarding subject safety, data integrity, and ethical conduct in clinical research.

Technical Writers | Quality Management System | Technical Writing

 

GCP QMS Requirements for Sponsor Companies

Sponsor companies bear the ultimate responsibility for the initiation, management, and financing of clinical trials. Their QMS must be capable of:

  • Ensuring compliance with ICH E6(R3), FDA 21 CFR Parts 312, 50, 54, and EMA guidelines
  • Managing risk and quality across the clinical development spectrum
  • Overseeing vendors, CROs, and clinical sites effectively
  • Documenting decisions and corrective actions throughout trial conduct

What is Quality Assurance in Pharma & Why Is It Important?

 

QMS Structure / Segments as per FDA, ICH & EMA

A well-structured GCP QMS should address the following core segments, aligning with ICH E6(R3), FDA Guidance for Industry – Q10, and EMA’s Reflection Papers:

1.     Governance & Oversight

  • Quality policy
  • Organizational structure
  • Management responsibilities and review processes

2.     Quality Risk Management

  • Risk identification and evaluation
  • Mitigation strategies
  • Risk-based monitoring (RBM)

3.     Document & Record Control

  • SOPs, policies, and manuals
  • Trial Master File (TMF) and audit trails
  • Version control and archival practices

4.     Training & Qualification

  • GCP training programs
  • Role-specific competency tracking
  • Vendor/CRO qualification

5.     Vendor Oversight

  • Qualification, selection, and management of CROs and third-party vendors
  • Performance monitoring
  • Contractual and regulatory compliance

6.     Audits & Inspections

  • Internal and external audits
  • CAPA (Corrective and Preventive Actions) system
  • Readiness for regulatory inspections

7.     CAPA & Continuous Improvement

  • Root cause analysis
  • Implementation and effectiveness verification
  • Lessons learned processes

8.     Deviation & Issue Management

  • Deviation reporting and analysis
  • Protocol deviation tracking
  • Escalation and resolution pathways

9.     Data Integrity & Systems Validation

  • Electronic system validation (CSV)
  • ALCOA+ principles
  • eSource and eTMF standards

10. Trial Oversight & Reporting

  • Oversight plans
  • DSURs, CSR submissions
  • Real-time metrics dashboards

Prime Components for Designing a Sponsor GCP QMS

To design a compliant and efficient GCP QMS for sponsors, focus on:

  • ICH E6(R3) implementation strategy
  • Cross-functional SOP integration
  • Vendor and CRO quality assurance plans
  • Digital quality management tools (eQMS)
  • Inspection readiness culture
  • Documentation lifecycle management

Why GxP Cellators Consultants?

GxP Cellators Consultants specializes in developing, implementing, and optimizing GCP QMS frameworks for sponsor companies of all sizes. With deep regulatory knowledge and hands-on experience, we tailor solutions that align with FDA, EMA, and ICH expectations.

Contact us today at:
Your partner in GxP compliance, clinical quality, and inspection readiness.

Bioanalytical GLP Consultants | GLP Consultants | OECD GLP

CONTINUE READING
by Vinod
17/04/2025
WFI_16042025-1-1280x853.webp
Clean and Dirty Utilities0

Clean and Dirty Utilities in Biologics Projects

Clean and Dirty Utilities in Biologics Projects

Clean Utilities

These utilities come into direct or indirect contact with the product, manufacturing environment, or packaging and must meet strict GMP (Good Manufacturing Practice) and GxP requirements.

Examples:

  • Purified Water (PW)
  • Water for Injection (WFI)
  • Clean Steam
  • Process Gases (Nitrogen, Compressed Air, CO₂, O₂ – when in contact with product)
  • HVAC for classified cleanroom environments

Purified Water | Water for Injections | Purified Water Systems

 

 

Commissioning of HVAC Systems

 

Dirty Utilities

These do not contact the product and are primarily used for support functions. They don’t require the same stringent GMP controls but must still be reliable.

Examples:

  • Chilled Water
  • Steam (Plant Steam)
  • Industrial Gases
  • Non-GMP HVAC
  • Waste Management Systems
  • Compressed Air (non-GMP)

Qualification Requirements: Clean vs. Dirty Utilities

Utility TypeQualification RequirementRegulatory Focus
Clean UtilitiesFull GMP qualification (IQ/OQ/PQ), Critical utility validation, Periodic requalificationFDA, EMA, WHO, etc.
Dirty UtilitiesEngineering qualification, Functional testing, Maintenance validationGEP (Good Engineering Practices)
Water for Injections I Clean Utilities I WFI I Purified Water I

 

Step-by-Step Utility Qualification Process

For Clean Utilities

1.     Design Qualification (DQ)

  • Ensure system design meets URS (User Requirements Specification)
  • Review P&IDs, specifications, and materials of construction
  • Document: DQ Report

2.     Installation Qualification (IQ)

  • Verify equipment/system is installed per design
  • Review calibration certificates, component tags, wiring, etc.
  • Document: IQ Protocol & Report

3.     Operational Qualification (OQ)

  • Test system operations against functional specs
  • Include alarm testing, control ranges, safety features
  • Document: OQ Protocol & Report

4.     Performance Qualification (PQ)

  • Test system under load conditions (e.g., actual production)
  • Monitor microbial/chemical parameters (e.g., for PW/WFI)
  • Document: PQ Protocol & Report

5.     Validation Summary Report

  • Summarize DQ-IQ-OQ-PQ
  • Justify operational acceptance
  • Document: VSR

6.     Periodic Review & Requalification

  • SOP-driven requalification
  • Trending & deviation reviews

For Dirty Utilities

1.     Engineering Design Review

  • Ensure GEP compliance
  • Evaluate efficiency, safety, capacity
  • Document: Engineering Design Assessment

2.     Installation & Functionality Check

  • Check installation as per design
  • Confirm operational capability
  • Document: System Verification Report

3.     Performance Tests (where required)

  • System pressure, flow, alarms
  • Calibration of key instruments
  • Document: Functionality/Performance Test Report

4.     Handover to Maintenance

  • Ensure preventive maintenance plan is in place
  • Document: Handover Certificate

Documentation Package

  • URS (User Requirements Specification)
  • FS/DS (Functional/Design Specification)
  • P&IDs, GA Drawings
  • Risk Assessment (FMEA)
  • DQ/IQ/OQ/PQ Protocols & Reports
  • Calibration & Maintenance Logs
  • Validation Master Plan (VMP)
  • SOPs (System Use, Sampling, Cleaning, Maintenance)
  • Traceability Matrix

GxP Cellators Consultants’ Expertise

GxP Cellators Consultants is a highly experienced team specializing in utility qualification for biologics manufacturing facilities, including greenfield and brownfield projects.

Services and Strengths:

1.     Clean & Dirty Utility Qualification

  • Turnkey qualification for PW, WFI, clean steam, gases
  • Engineering qualification in chilled water, plant steam, HVAC, and more

2.     Qualification Documentation Design

  • Custom protocol development (DQ, IQ, OQ, PQ)
  • Risk-based qualification approach aligned with ISPE & FDA guidelines

3.     On-Site Execution Support

  • Expert-led testing and validation
  • Deviation management, change control, CAPA documentation

4.     Site Utilities and HVAC Systems

  • Full commissioning and qualification of HVAC (cleanroom grades A-D)
  • Airflow visualization (smoke studies), recovery rate, pressure cascade validation

5.     GMP Readiness Programs

  • End-to-end support for GMP inspections
  • Readiness gap assessments and remediation plans
  • Regulatory audit support and technical documentation review

Commissioning Qualification and Validation I CQV Services I GxP

CONTINUE READING
by Vinod
13/04/2025
Biosafety-Cabinet-1280x698.webp
Biosafety Cabinets0

Biosafety Cabinets

Biosafety Cabinets: Why Are They Required?

Biosafety Cabinets (BSCs) are essential engineering controls in laboratories that handle potentially infectious agents or hazardous biological materials. They serve as a critical barrier between hazardous substances and the laboratory environment.

Analytical Instrument & System Qualification | Analytical Validation

 

BSCs are specifically designed to:

  • ✅ Protect personnel from exposure to harmful biological agents and pathogens.
  • ✅ Protect the environment by containing and filtering biohazardous aerosols before release.
  • ✅ Maintain product integrity (in Class II and III cabinets) by minimizing contamination during sensitive procedures.

Biosafety Cabinets are a cornerstone of modern biosafety practices. Their use supports compliance with global regulatory requirements and guidelines established by organizations such as the CDC, WHO, and NIH, and they are often mandated under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) environments.

Laminar Air Flow vs. Biosafety Cabinets

While both Laminar Air Flow (LAF) cabinets and Biosafety Cabinets control the air environment to protect samples or personnel, they serve very different purposes:

FeatureLaminar Air Flow (LAF) CabinetBiosafety Cabinet (BSC)
Primary PurposeProtects product/samplesProtects personnel, environment, and product (Class II)
Air Flow DirectionHorizontal or vertical laminar flowVertical laminar flow with HEPA-filtered exhaust
Exhaust AirRecirculated into the roomHEPA-filtered, some may be ducted outside
Protection for Operator❌ Not provided✅ Yes
Use with Pathogens❌ Not suitable✅ Required for biohazardous work

Bottom Line: LAFs should never be used when working with infectious materials. BSCs are the standard for biosafety.

Qualifications of Biosafety Cabinets

To ensure a BSC operates safely and as intended, it must undergo a series of qualifications:

  1. Design Qualification (DQ) – Verifies that the selected BSC meets intended specifications and regulatory needs.
  2. Installation Qualification (IQ) – Ensures that the BSC is installed correctly per manufacturer specifications.
  3. Operational Qualification (OQ) – Confirms that the cabinet performs according to operational parameters (e.g., airflow velocity, HEPA filter integrity).
  4. Performance Qualification (PQ) – Demonstrates consistent performance under simulated or actual conditions of use.

Cleanroom Documentation | Cleanroom Documentation Package

 

Step-by-Step Guidance for Qualifying Biosafety Cabinets

  1. Pre-Qualification Planning

  1. Installation Qualification (IQ)

  • Verify model, serial number, and manufacturer documentation
  • Ensure proper location (no cross-drafts, away from traffic)
  • Check electrical connections and certifications

  1. Operational Qualification (OQ)

  • Conduct airflow velocity tests
  • Perform HEPA filter integrity test (DOP/PAO challenge)
  • Validate alarms and control panel functionality
  • Test lighting, blower motor, UV light (if present)

  1. Performance Qualification (PQ)

  • Simulate actual usage conditions
  • Confirm the absence of contamination during mock runs
  • Monitor pressure differentials and airflow under load

  1. Documentation & Certification

  • Record all test results and deviations
  • Issue certification label and report
  • Schedule periodic requalification (annually or as required)

Pros and Cons of Biosafety Cabinets

ProsCons
✅ Ensures safety of personnel and environment❌ Higher initial cost compared to LAF units
✅ Mandatory for pathogen or hazardous material handling❌ Requires regular maintenance and HEPA filter replacement
✅ Complies with biosafety and regulatory standards❌ Improper use or placement can compromise protection
✅ Various classes for different protection levels (I, II, III)❌ Not suitable for volatile chemicals unless specialized

Need Help Qualifying Your Biosafety Cabinet?

Reach out to GxP Cellators Consultants.
They are recognized Subject Matter Experts (SMEs) in equipment qualifications and can provide:

  • End-to-end qualification services (DQ, IQ, OQ, PQ)
  • Customized protocols per regulatory and operational needs
  • Certification, documentation, and audit support

📞 Contact GxP Cellators today to ensure your biosafety cabinet is fully compliant and operational.

CONTINUE READING
by Vinod
09/04/2025
Analytical-Instrument-and-System-Qualification-1280x698.webp
Equipment Qualifications0

Analytical Instrument and System Qualification (AISQ)

Purpose

USP <1058> provides a scientific and risk-based framework for the qualification of analytical instruments and systems to ensure they are fit for their intended use throughout their operational life cycle.

This guidance emphasizes:

  • Integration of hardware, firmware, and software
  • The importance of data integrity, accuracy, and reliability
  • Support for regulatory compliance in pharmaceutical analysis

It applies to all types of instruments, from simple apparatus to complex computerized systems—and promotes a life cycle approach that includes selection, qualification, performance monitoring, and change management.

Core Concepts

🔹 Fitness for Intended Use

AISQ ensures that instruments and systems:

  • Function correctly
  • Generate reliable, quality data
  • Are suitable for their intended analytical applications

Risk-Based Classification

Instruments are classified based on complexity and criticality:

GroupTypeExamplesQualification Need
ASimple apparatusVortex mixer, glasswareMinimal to none
BIntermediate instrumentspH meter, ovensCalibration, basic checks
CComplex systemsHPLC, mass spectrometersFull qualification, software validation

Further subcategories (A1–C3) add granularity based on software complexity (e.g., configurable/custom modules).

HPLC UPLC Qualifications | Chromatographic Systems | QMS

 

 

Life Cycle Qualification Approaches

✅ 4Qs Model

  1. Design Qualification (DQ) – Confirms suitability before purchase
  2. Installation Qualification (IQ) – Verifies proper delivery and setup
  3. Operational Qualification (OQ) – Ensures correct function per specifications
  4. Performance Qualification (PQ) – Confirms consistent performance in actual use

Note: May include Factory/Site Acceptance Testing (FAT/SAT)

🔄 Integrated Life Cycle Approach

  • Aligns AISQ with Analytical Procedure and Process Validation life cycles
  • Emphasizes continuous assurance over time
  • Phases:
    1. Specification & Selection
    2. Installation & Qualification
    3. Ongoing Performance Verification

HPLC UPLC Qualifications | Chromatographic Systems | QMS

Key Activities and Documentation

  • User Requirement Specification (URS): Foundation for qualification
  • Calibration: Per relevant general chapters
  • Software Validation: Integrated with AISQ where possible
  • Change Control: Required for hardware/software changes
  • Ongoing Monitoring: Includes preventive maintenance, periodic review

Components of Quality Data

  1. Analytical Instrument Qualification (AIQ)
  2. Analytical Method Validation
  3. System Suitability Tests (SSTs)
  4. Quality Control Check Samples

Roles & Responsibilities

  • Users: Own qualification activities; responsible for URS, testing, documentation
  • Quality Unit: Ensures compliance, reviews qualification
  • Suppliers/Manufacturers: Provide specifications, support, and documentation
  • Consultants/Service Providers: May assist, but final responsibility remains with the user

Key Takeaways

  • AISQ is not a one-time activity but a life-cycle commitment
  • Risk and intended use determine qualification rigor
  • Harmonization with chapters like <1220>, <1225>, <1029>, and <1039> is encouraged
  • Data integrity, traceability, and proper documentation are critical

Contact Us

GxP Cellators is a reputable contract services organization offering a wide range of Good x Practices (GxP) services across Manufacturing, Laboratory, Distribution, Engineering, and Clinical practices. We serve various industries, including pharmaceuticals, biopharmaceuticals, medical devices, and cannabis. Our team works closely with esteemed clients in the life sciences sector to support the development of greenfield and brownfield projects, guiding them from the initial project stage to regulatory approval for their GxP sites.

Our team is composed of highly qualified experts specializing in Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), Good Clinical Practices (GCP), Good Distribution Practices (GDP), Cleanroom Operations, and Engineering Operations. Our Subject Matter Experts (SMEs) are extensively trained and possess the necessary knowledge and skills to excel in their respective fields.

Additionally, we have a skilled team of validation specialists with expertise in qualifications for equipment and utilities, computerized system validations (CSV), thermal validations, clean utilities validation, and cleanroom validations. For assistance qualifying your facilities or site equipment, please get in touch with us at .

CONTINUE READING
by Vinod
02/04/2025
Medical-Devices-License.webp
Medical Devices License0

Medical Devices License I MDL I MDEL

In Canada, Health Canada regulates medical devices, ensuring their safety, effectiveness, and quality. The primary legislation governing medical devices is the Medical Devices Regulations (MDR) under the Food and Drugs Act. Companies manufacturing, importing, or distributing medical devices must comply with these regulations to ensure their devices meet Canadian requirements.

Medical Devices: The categories and the regulatory landscape | GxP Cellators Consultants Ltd.

 

Types of Licenses Required for Medical Devices in Canada

The licenses required in Canada for medical devices depend on the company’s role in the device’s lifecycle, such as manufacturing, research, distribution, and storage. These licenses ensure that medical devices meet regulatory requirements before being marketed and sold.

  1. Medical Device Establishment License (MDEL)

    • Required for: Companies that import or distribute medical devices in Canada. This includes companies selling, leasing, or providing medical devices to healthcare providers.
    • Issued by: Health Canada
    • Requirements:
      • The establishment must meet the requirements outlined in the Medical Devices Regulations.
      • The company must have a Quality Management System (QMS), which could be ISO 13485 or another acceptable standard.
      • Companies must report adverse events and device recalls to Health Canada.

  1. Medical Device License (MDL)

    • Required for: Manufacturers who want to sell medical devices in Canada.
    • Issued by: Health Canada
    • Requirements:
      • A medical device manufacturer must apply for a license that includes evidence that the device is safe and effective for its intended use.
      • The manufacturer must demonstrate that they follow appropriate Good Manufacturing Practices (GMP).
      • Health Canada reviews clinical evidence, pre-market data, and risk management documentation.

GMP Auditing Services I GMP Audits I GMP Auditors I

 

  1. Site License (for Manufacturing or Importation)

    • Required for: Medical device manufacturers or importers conducting activities related to medical devices within Canada.
    • Issued by: Health Canada
    • Requirements:
      • The facility must comply with GMP and other regulatory requirements.
      • Includes the need for a detailed QMS that adheres to ISO 13485

Types of Medical Devices in Canada

Medical devices are categorized based on risk level, and the regulatory requirements differ for each class. These categories are:

  1. Class I (Low Risk)

    • Examples: Bandages, non-prescription surgical instruments, stethoscopes, etc.
    • Licensing Requirements: These devices generally require an MDEL but not a full Medical Device License (MDL). They do not need a detailed review before being marketed, but manufacturers must ensure they meet regulatory requirements.

  2. Class II (Moderate Risk)

    • Examples: Syringes, infusion pumps, and dental materials.
    • Licensing Requirements: These devices require an MDL and compliance with regulatory standards for safety and effectiveness.

  3. Class III (High Risk)

    • Examples: Pacemakers, ventilators, and certain types of diagnostic equipment.
    • Licensing Requirements: These devices require extensive pre-market approval, including clinical trial data and an MDL. Manufacturers must also demonstrate compliance with GxP (Good Clinical Practices) and other quality standards.

  4. Class IV (Very High Risk)

    • Examples: Implantable devices such as heart valves and other life-sustaining equipment.
    • Licensing Requirements: These devices require the highest level of scrutiny, including detailed clinical data, pre-market approval, and full compliance with all regulatory frameworks, including ISO 13485.

Types of Licenses Related to Medical Devices

Besides the MDEL and MDL, companies may also need specific licenses or certifications. These include:

  1. Manufacturing License

    • Required for: Companies involved in designing, manufacturing, or modifying medical devices.
    • Regulatory Requirements: The company must have a certified QMS that complies with ISO 13485 and follow GMP. It must also demonstrate the ability to ensure device quality and safety through effective manufacturing practices.

  2. Research License

    • Required for: Companies involved in medical device research and clinical testing.
    • Regulatory Requirements: Research and testing involving human participants require compliance with Good Clinical Practices (GCP), ethical approval, and other regulatory compliance measures. Health Canada oversees these clinical trials and research activities.

  3. Distribution License (MDEL)

    • Required for: Companies that distribute medical devices within Canada but do not manufacture them. This can include wholesalers or importers.
    • Regulatory Requirements: The distributor must adhere to Health Canada’s standards for device safety, quality, and adverse event reporting. They must also maintain traceability and ensure that devices are only sold compliantly.

  4. Storage and Importation

    • Required for: Companies involved in medical device storage, warehousing, or distribution.
    • Regulatory Requirements: Companies must ensure the proper storage conditions for devices (e.g., temperature and humidity control) and may require an MDEL if they import or sell medical devices.

Role of GxP Cellators in Regulatory Compliance

GxP Cellators is a consulting firm that helps medical device companies establish their Quality Management Systems (QMS) in compliance with industry standards, such as ISO 13485 and MDSAP (Medical Device Single Audit Program). They assist companies in meeting the rigorous requirements of Canadian and international markets.

Key Areas GxP Cellators Can Assist With:

  1. ISO 13485 Certification:

    • This standard specifies the requirements for a QMS that organizations must implement in the design, production, installation, and servicing of medical devices.
    • GxP Cellators helps organizations set up the appropriate processes to meet the certification standards.

  2. MDSAP:

    • The Medical Device Single Audit Program (MDSAP) allows manufacturers to undergo a single audit to satisfy the regulatory requirements of multiple countries (including Canada, the U.S., Japan, Brazil, and Australia).
    • GxP Cellators can help prepare companies for MDSAP audits and ensure compliance with the standards.

  3. Regulatory Licensing:

    • GxP Cellators helps companies obtain the necessary Medical Device Licenses (MDL), MDEL, and other regulatory approvals to enter the Canadian market.

  4. Risk Management & Compliance:

    • Helping companies implement risk management practices and comply with regulations for medical devices, including post-market surveillance, adverse event reporting, and product recall procedures.

  5. Training and Documentation:

    • Providing training on regulatory requirements and maintaining comprehensive documentation that supports licensing applications, audits, and inspections.

 

CONTINUE READING
by Vinod
30/03/2025
Cleanroom-documentation_29032025.webp
Cleanroom documentation0

Cleanroom Documentation

The Cleanroom Documentation Package (CDP) is a critical set of documents that ensures cleanrooms meet industry standards and regulations for use in controlled environments, such as pharmaceutical or biotech manufacturing. The Cleanroom Qualification and Validation (CQV) process is a structured approach to validating that the cleanroom operates as required and can maintain the necessary cleanliness levels, environmental conditions, and operational parameters. Below is a list of CQV documentation required for cleanrooms, along with a brief description of each document:

Cleanrooms | Cleanroom Consulting | Biotech Cleanrooms

 

1.     Cleanroom CQV-Construction Plan

Purpose:
The Construction Plan outlines the scope, timeline, resources, and methodologies for building the cleanroom facility, ensuring the project aligns with operational needs and regulatory requirements.

Contents:

  • Project scope and objectives
  • Construction schedule and milestones
  • Resource planning (personnel, equipment, materials)
  • Risk assessment and mitigation strategies
  • Design specifications for HVAC, lighting, air filtration, and other critical systems
  • Project management structure and roles
  • Compliance with regulatory standards (e.g., GMP, ISO)

Construction Plan for a Biologics Manufacturing Facility

2.    User Requirements Specification (URS)

Purpose:
The URS defines the specific requirements the cleanroom must meet based on the intended application. It serves as the foundation for the cleanroom’s design and validation process.

Contents:

  • Functional requirements (e.g., air cleanliness levels, temperature, humidity, pressure differentials)
  • Process requirements (e.g., product or equipment compatibility with the cleanroom environment)
  • Safety standards and operational limits
  • GxP compliance requirements
  • Environmental monitoring criteria
  • Utilities and system specifications (e.g., HVAC, electrical, water systems)

User Requirements Specification | Cleanrooms | Cleanroom URS

3.    Validation Plans

Purpose:
The Validation Plans provide a structured approach to qualifying and validating the cleanroom, ensuring it operates as intended and meets all relevant regulatory requirements.

Contents:

  • Overview of the qualification strategy (IQ, OQ, PQ)
  • Detailed test plans for Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)
  • Roles and responsibilities of personnel
  • Testing protocols and procedures
  • Acceptance criteria for each qualification phase
  • Risk management strategies for validation activities
  • Timeline for completion of qualification tasks

4.    Installation Qualification (IQ)

Purpose:
IQ verifies that the cleanroom and its critical systems (e.g., HVAC, filtration, utilities) have been installed correctly and meet the design specifications in the URS.

Contents:

  • Verification of equipment installation (e.g., air handling units, HEPA filters)
  • System documentation review (e.g., design drawings, equipment manuals)
  • Calibration of installed equipment
  • Inspection of utilities and infrastructure
  • Compliance checks with specifications
  • Performance of installation tests (e.g., airflow patterns, pressure differentials)

Biologics Manufacturing I Cleanroom Design Qualification Process

5.    Operational Qualification (OQ)

Purpose:
OQ ensures that the cleanroom and its systems operate as designed under normal conditions. It confirms that systems function according to predefined operational parameters.

Contents:

  • Functional testing of cleanroom systems (e.g., air circulation, pressure control, temperature)
  • Verification of system performance under load (e.g., number of personnel, equipment in operation)
  • Testing of critical environmental parameters (e.g., particulate counts, airflow, temperature and humidity stability)
  • Operational system checks (e.g., pressure differentials, airflow validation)
  • Compliance with URS and regulatory standards

6.    Performance Qualification (PQ)

Purpose:
PQ verifies that the cleanroom performs consistently and reliably under typical operating conditions over time, ensuring the cleanroom environment is stable for ongoing operations.

Contents:

  • Long-term performance testing (e.g., continuous monitoring of air quality, temperature, humidity, and pressure)
  • Validation of system robustness under real production conditions (e.g., testing with operational equipment running)
  • Verification that cleanroom maintains required cleanliness and environmental conditions throughout routine operations
  • Documentation of performance data over a defined qualification period
  • Analysis of system stability and consistency over time

Cleanroom EMPQ | Cleanrooms | Cleaning Validation

7.    Summary Reports

Purpose:
Summary reports compile the results of the IQ, OQ, and PQ phases and provide a final review of the cleanroom’s qualification status, confirming its suitability for use.

Contents:

  • Overview of the qualification process (IQ, OQ, PQ) and outcomes
  • Summary of testing results and deviations (if any)
  • Corrective actions taken and resolutions
  • Final assessment of cleanroom readiness
  • Recommendations for continued monitoring and maintenance
  • Certification of compliance with regulatory requirements

8.    Operational Standard Operating Procedures (SOPs)

Purpose:
Operational SOPs provide detailed instructions for the cleanroom’s daily operations, maintenance, and monitoring. These procedures ensure consistent, reliable operation and ongoing compliance with GxP regulations.

Contents:

  • Cleanroom entry and gowning procedures
  • Cleaning and disinfection protocols (e.g., surface cleaning, air handling systems maintenance)
  • Environmental monitoring procedures (e.g., particle count, air quality checks)
  • Equipment maintenance and calibration schedules
  • Emergency procedures (e.g., system failures, contamination incidents)
  • Change control procedures for modifying cleanroom operations
  • Documentation practices (e.g., logbooks, maintenance records)

Role of GxP Cellators in Cleanroom Documentation and Operations:

GxP Cellators, or similar entities, are vital in providing and executing the Cleanroom Documentation Package. They are involved in:

  • Preparing and delivering the full documentation package covering all cleanroom qualification and validation aspects.
  • Execute qualification activities (IQ, OQ, PQ), perform required tests, and ensure systems operate within specifications.
  • Provide support for regulatory compliance and ensure all documentation meets GxP standards (e.g., FDA, EMA).
  • Train staff in operational procedures (SOPs) and guide proper cleanroom operations and maintenance practices.
  • Supporting ongoing monitoring and requalification efforts to maintain cleanroom performance over time.

This package ensures that the cleanroom is fit for use, compliant with regulations, and capable of maintaining a controlled environment suitable for the intended applications, whether for pharmaceutical production, medical device manufacturing, or other regulated industries.

For any assistance needed with cleanroom documentation design, please get in touch with GxP Cellators at .

Cleanroom Consultants I Cleanroom CQV I Biologics Project

 

 

CONTINUE READING

Newer Posts

Older Posts

Our Presence

Saskatchewan, Canada
Calgary, Canada
Toronto, Canada
North Carolina, USA
Frankfurt, Germany
Indiana, USA

Get in Touch

+1 (306) 715 -9460
Saskatchewan, Canada
https://www.gxpcellators.com

Our Services

Commissioning, Qualifications & Validations
Cleanroom Commissioning & Qualifications
Engineering
Project Management
Quality Support
Regulatory Support

You cannot copy content of this page

Verified by MonsterInsights